Advances in systemic therapy for psoriasis.
Severe cases of psoriasis and psoriasis arthritis require systemic treatment. Although a number of established drugs are in clinical use, there is a need for new compounds with an improved risk-benefit ratio with a major emphasis on long-term safety. Furthermore, patients with moderate psoriasis ask for systemic drugs to make therapy easier and to avoid excessive local treatments. This article aims to give a brief overview about new drugs or groups of compounds together with an evaluation of their present status in the treatment of psoriasis and their future role with particular respect to efficacy, tolerability, safety and usability.
Mrowietz
U
U
Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany. umrowietz@dermatology.uni-kiel.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000938:Antigen-Presenting Cells / Q000276:immunology; D015535:Arthritis, Psoriatic / Q000276:immunology / Q000628:therapy; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D007641:Keratolytic Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011565:Psoriasis / Q000276:immunology / Q000628:therapy*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism
D000911:Antibodies, Monoclonal; D016588:Anticarcinogenic Agents; D003879:Dermatologic Agents; D005650:Fumarates; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D010975:Platelet Aggregation Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors